Fagron Posts 23% Revenue Growth in Q3, Confirms Full-Year Outlook…

Event summary

Fagron reported €281.3 million in Q3 revenue, up 23.2% YoY (19.5% at CER), driven by EMEA, Latin America, and Brands & Essentials in North America–Pacific.
Organic growth at CER was 3.4%, with EMEA at 6.5%, Latin America at 9.7%, and Brands & Essentials in North America–Pacific at 26.1%.
Completed acquisition of Injeplast in Brazil; all previously announced acquisitions are now closed and integrating well.
FY 2026 revenue outlook confirmed at €1,125 – €1,150 million with an adj. EBITDA margin of 19.5% – 20.0%.
North America–Pacific Compounding Services impacted by temporary IV bag recall, expected to recover in Q4.

The big picture

Fagron's strong Q3 performance highlights the resilience of its diversified model, with robust growth in EMEA and Latin America offsetting temporary setbacks in North America–Pacific. The completion of all announced acquisitions and the focus on disciplined M&A reflect a strategic push to strengthen its global position. The company's confidence in maintaining its FY guidance suggests a stable outlook, but the recovery in North America–Pacific remains a critical watchpoint.

What we're watching

Market Recovery: The pace at which North America–Pacific Compounding Services recovers from the IV bag recall will determine Q4 performance.
Integration Risk: Whether Fagron can sustain the momentum from recent acquisitions, particularly Injeplast in Brazil.
Strategic Positioning: How Fagron's expansion projects and acquisitions contribute to its global leadership in pharmaceutical compounding.